Wong WL et al (2014) Global prevalence of age-related macular degeneration and disease burden projection for 2020 and 2040: a systematic review and meta-analysis. Lancet Glob Health 2(2):e106–e116

Article  PubMed  Google Scholar 

Flaxman SR et al (2017) Global causes of blindness and distance vision impairment 1990–2020: a systematic review and meta-analysis. Lancet Glob Health 5(12):e1221–e1234

Article  PubMed  Google Scholar 

Mullard A (2021) FDA approves 100th monoclonal antibody product. Nat Rev Drug Discov 20:491–495. https://doi.org/10.1038/d41573-021-00079-7

Article  CAS  PubMed  Google Scholar 

Kroschinsky F et al (2017) New drugs, new toxicities: severe side effects of modern targeted and immunotherapy of cancer and their management. Critical care (London, England) 21(1):89–89

Article  PubMed  Google Scholar 

Perez VL et al (2013) The eye: a window to the soul of the immune system. J Autoimmun 45:7–14

Article  CAS  PubMed  Google Scholar 

Eaton JS et al (2015) Ocular adverse events associated with antibody-drug conjugates in human clinical trials. J Ocul Pharmacol Ther 31(10):589–604

Article  CAS  PubMed  PubMed Central  Google Scholar 

Ho WL, Wong H, Yau T (2013) The ophthalmological complications of targeted agents in cancer therapy: what do we need to know as ophthalmologists? Acta Ophthalmol 91(7):604–609

Article  PubMed  Google Scholar 

Vishnevskia-Dai V et al (2021) Ocular side effects of novel anti-cancer biological therapies. Sci Rep 11(1):787

Article  CAS  PubMed  PubMed Central  Google Scholar 

Zernii EY et al (2016) Rabbit models of ocular diseases: new relevance for classical approaches. CNS Neurol Disord Drug Targets 15(3):267–291

Article  CAS  PubMed  Google Scholar 

Picaud S et al (2019) The primate model for understanding and restoring vision. Proc Natl Acad Sci 116(52):26280

Article  CAS  PubMed  PubMed Central  Google Scholar 

Fernandes A et al (2003) Ocular measurements throughout the adult life span of rhesus monkeys. Invest Ophthalmol Vis Sci 44(6):2373–2380

Article  PubMed  Google Scholar 

Chang B (2013) Mouse models for studies of retinal degeneration and diseases. Methods Mol Biol 935:27–39

Article  CAS  PubMed  Google Scholar 

Hutton-Smith LA et al (2016) A mechanistic model of the intravitreal pharmacokinetics of large molecules and the pharmacodynamic suppression of ocular vascular endothelial growth factor levels by ranibizumab in patients with neovascular age-related macular degeneration. Mol Pharm 13(9):2941–2950

Article  CAS  PubMed  Google Scholar 

Hutton-Smith LA et al (2017) Ocular pharmacokinetics of therapeutic antibodies given by intravitreal injection: estimation of retinal permeabilities using a 3-compartment semi-mechanistic model. Mol Pharm 14(8):2690–2696

Article  CAS  PubMed  Google Scholar 

Park SJ et al (2016) Intraocular pharmacokinetics of intravitreal aflibercept (eylea) in a rabbit model. Invest Ophthalmol Vis Sci 57(6):2612–2617

Article  CAS  PubMed  Google Scholar 

Mordenti J et al (1999) Comparisons of the intraocular tissue distribution, pharmacokinetics, and safety of 125I-labeled full-length and Fab antibodies in rhesus monkeys following intravitreal administration. Toxicol Pathol 27(5):536–544

Article  CAS  PubMed  Google Scholar 

Shah DK, Betts AM (2012) Towards a platform PBPK model to characterize the plasma and tissue disposition of monoclonal antibodies in preclinical species and human. J Pharmacokinet Pharmacodyn 39(1):67–86

Article  CAS  PubMed  Google Scholar 

Bussing D, Dhaval KS (2020) Development of a physiologically-based pharmacokinetic model for ocular disposition of monoclonal antibodies in rabbits. J Pharmacokinet Pharmacodyn 47(6):597–612

Article  CAS  PubMed  PubMed Central  Google Scholar 

Rohatgi, A., Webplotdigitizer: Version 4.5.

Hinton PR et al (2004) Engineered human IgG antibodies with longer serum half-lives in primates. J Biol Chem 279(8):6213–6216

Article  CAS  PubMed  Google Scholar 

Lin YS et al (1999) Preclinical pharmacokinetics, interspecies scaling, and tissue distribution of a humanized monoclonal antibody against vascular endothelial growth factor. J Pharmacol Exp Ther 288(1):371–378

CAS  PubMed  Google Scholar 

Miyake T et al (2010) Pharmacokinetics of bevacizumab and its effect on vascular endothelial growth factor after intravitreal injection of bevacizumab in macaque eyes. Invest Ophthalmol Vis Sci 51(3):1606–1608

Article  PubMed  Google Scholar 

Yu DA et al (2018) Preclinical pharmacokinetics of a recombinant humanized rabbit anti-VEGF monoclonal antibody in rabbits and monkeys. Toxicol Lett 292:73–77

Article  CAS  PubMed  Google Scholar 

Curtin F et al (2016) Serum pharmacokinetics and cerebrospinal fluid concentration analysis of the new IgG4 monoclonal antibody GNbAC1 to treat multiple sclerosis: a phase 1 study. MAbs 8(5):854–860

Article  CAS  PubMed  PubMed Central  Google Scholar 

Weisman MH et al (2003) Efficacy, pharmacokinetic, and safety assessment of adalimumab, a fully human anti-tumor necrosis factor-alpha monoclonal antibody, in adults with rheumatoid arthritis receiving concomitant methotrexate: a pilot study. Clin Ther 25(6):1700–1721

Article  CAS  PubMed  Google Scholar 

Markus R et al (2017) A phase I, randomized, single-dose study evaluating the pharmacokinetic equivalence of biosimilar ABP 215 and bevacizumab in healthy adult men. Cancer Chemother Pharmacol 80(4):755–763

Article  CAS  PubMed  PubMed Central  Google Scholar 

Knight B et al (2016) A phase I pharmacokinetics study comparing PF-06439535 (a potential biosimilar) with bevacizumab in healthy male volunteers. Cancer Chemother Pharmacol 77(4):839–846

Article  CAS  PubMed  PubMed Central  Google Scholar 

Avery RL et al (2017) Systemic pharmacokinetics and pharmacodynamics of intravitreal aflibercept, bevacizumab and ranibizumab. Retina 37(10):1847–1858

Article  CAS  PubMed  PubMed Central  Google Scholar 

Krohne TU et al (2008) Intraocular pharmacokinetics of bevacizumab after a single intravitreal injection in humans. Am J Ophthalmol 146(4):508–512

Article  CAS  PubMed  Google Scholar 

Meyer CH, Krohne TU, Holz FG (2011) Intraocular pharmacokinetics after a single intravitreal injection of 1.5 mg versus 3.0 mg of bevacizumab in humans. Retina 31(9):1877–1884

Article  CAS  PubMed  Google Scholar 

Zhu Q et al (2008) Vitreous levels of bevacizumab and vascular endothelial growth factor-A in patients with choroidal neovascularization. Ophthalmology 115(10):1750–1755

Article  PubMed  Google Scholar 

D’Argenio DZ, Schumitzky A, Wang X (2009) ADAPT 5 User’s guide: pharmacokinetic/pharmacodynamic systems analysis software. Biomedical Simulations Resource, Los Angeles

Google Scholar 

Smith DW, Lee CJ, Gardiner BS (2020) No flow through the vitreous humor: How strong is the evidence? Prog Retin Eye Res 78:100845

Article  CAS  Google Scholar 

Chang HY et al (2019) A translational platform PBPK model for antibody disposition in the brain. J Pharmacokinet Pharmacodyn 46(4):319–338

Article  CAS  PubMed  PubMed Central  Google Scholar 

Missel PJ (2012) Simulating intravitreal injections in anatomically accurate models for rabbit, monkey, and human eyes. Pharm Res 29(12):3251–3272

Article  CAS  PubMed  PubMed Central  Google Scholar 

Short BG (2008) Safety evaluation of ocular drug delivery formulations: techniques and practical considerations. Toxicol Pathol 36(1):49–62

Article  CAS  PubMed  Google Scholar 

Vézina M (2013) Comparative ocular anatomy in commonly used laboratory animals. In: Weir AB, Collins M (eds) Assessing ocular toxicology in laboratory animals. Humana Press, Totowa, NJ, pp 1–21

Google Scholar 

Rowe-Rendleman CL et al (2014) Drug and gene delivery to the back of the eye: from bench to bedside. Invest Ophthalmol Vis Sci 55(4):2714–2730

Article  CAS  PubMed  PubMed Central  Google Scholar 

Cauvin AJ, Peters C, Brennan F (2015) Advantages and limitations of commonly used nonhuman primate species in research and development of biopharmaceuticals. The nonhuman primate in nonclinical drug development and safety assessment. Elsevier, Amsterdam, pp 379–395